Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP grew its holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 39.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,470,700 shares of the company's stock after purchasing an additional 416,600 shares during the quarter. Two Sigma Advisers LP owned 1.62% of Caribou Biosciences worth $2,338,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Centric Wealth Management purchased a new position in shares of Caribou Biosciences in the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. boosted its stake in shares of Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after purchasing an additional 21,416 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after purchasing an additional 9,148 shares during the period. Diametric Capital LP purchased a new position in shares of Caribou Biosciences in the fourth quarter valued at approximately $42,000. Finally, US Bancorp DE lifted its stake in Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after acquiring an additional 26,467 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Down 8.0%

Caribou Biosciences stock traded down $0.09 during trading on Monday, reaching $0.97. The stock had a trading volume of 2,427,298 shares, compared to its average volume of 1,458,007. Caribou Biosciences, Inc. has a 52-week low of $0.66 and a 52-week high of $3.00. The business has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.31. The stock has a market cap of $90.67 million, a PE ratio of -0.59 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. On average, equities analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $7.40.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.